• U.S. sales up 27.9% to A$41.2m
• Rest of World sales up 28.6% to A$12.9m
• Total group revenue including BARDA up 22.8% to A$59.9m

PolyNovo Limited (PolyNovo or Company) has provided indicative trading results for the first half of FY25. The Company reported strong performance, with U.S. sales up 27.9% to A$41.2 million and Rest of World sales up 28.6% to A$12.9 million, including strong performances in the UK/Ireland, Spain, Germany, Turkey, and Hong Kong. The Company also made its first sales in Malta, Portugal, and Peru. Total group revenue, including BARDA, increased by 22.8% to A$59.9 million compared to the same period last year. Chief Executive Officer, Swami Raote, highlighted that as the Company expands its NovoSorb platform and leadership beyond difficult burns to the broader Plastic & Reconstructive Surgery space, it is healing patients and delivering positive outcomes at a rate more than twice as fast as revenue growth. The Company also had a successful meeting with the FDA, during which the agency agreed that PolyNovo has sufficient data to submit an application for PMA approval.

The Company intends to disclose the audited 1H FY25 results on 24 February 2025.